A review of selected systemic antifungal drugs for use in dogs and cats - Veterinary Medicine
  • SEARCH:
Medicine Center
DVM Veterinary Medicine Featuring Information from:

ADVERTISEMENT

A review of selected systemic antifungal drugs for use in dogs and cats
This pharmacologist reviews a few of your antifungal choices, specifically the azoles andterbinafine. These drugs have a broad spectrum of activity—with some important differences.


VETERINARY MEDICINE


26. Odds FC, Cheesman SL, Abbott AB. Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro. J Antimicrob Chemother 1986;18(4):473-478.

27. Brito EH, Fontenelle RO, Brilhante RS, et al. Phenotypic characterization and in vitro antifungal sensitivity of Candida spp. and Malassezia pachydermatis strains from dogs. Vet J 2007;174(1):147-153.

28. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 1985;28(5):648-653.

29. Vaden SL, Heit MC, Hawkins EC, et al. Fluconazole in cats: pharmacokinetics following intravenous and oral administration and penetration into cerebrospinal fluid, aqueous humour and pulmonary epithelial lining fluid. J Vet Pharmacol Ther 1997;20(3):181-186.

30. Mastroiacovo P, Mazzone T, Botto LD, et al. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol 1996;175(6):1645-1650.

31. Roffey SJ, Cole S, Comby P, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 2003;31(6):731-741.

32. European Medicines Agency. Vfend. European Public Assessment Report (EPAR). Available at: http:// http://www.emea.europa.eu/humandocs/Humans/EPAR/vfend/vfend.htm. Accessed 08/01/2007.

33. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50(6):2009-2015.

34. European Medicines Agency. Posaconazole SP. European Public Assessment Report (EPAR). Available at: http:// http://www.emea.europa.eu/humandocs/Humans/EPAR/posaconazoleSP/posaconazoleSP.htm. Accessed 08/01/2007.

35. Nomeir AA, Kumari P, Hilbert MJ, et al. Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother 2000;44(3):727-731.

36. McLellan GJ, Aquino SM, Mason DR, et al. Use of posaconazole in the management of invasive orbital aspergillosis in a cat. J Am Anim Hosp Assoc 2006;42(4):302-307.

37. Kotnik T, Kozuh Erzen N, Kuzner J, et al. Terbinafine hydrochloride treatment of Microsporum canis experimentally-induced ringworm in cats. Vet Microbiol 2001;83(2):161-168

38. Kotnik T. Drug efficacy of terbinafine hydrochloride (Lamisil) during oral treatment of cats, experimentally infected with Microsporum canis. J Vet Med B Infect Dis Vet Public Health 2002;49(3):120-122.

39. Shadomy S, Espinel-Ingroff A, Gebhart RJ. In-vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouraudia 1985;23(2):125-132.

40. Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother 1987;31(9):1365-1368.

41. Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol 1989;14(2):110-113.


ADVERTISEMENT

Source: VETERINARY MEDICINE,
Click here